Loading…
Employees: 196
Size Jacobio Pharmaceuticals (1167.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $468M, the 771st largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$4.66 on 6 Nov 2026.
Performance Over six months the shares fell 27.4%, against -5.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 286.2% over the last twelve months (peer median -4.0%); the operating margin is 68.0% (peer median -27.2%).
Valuation It trades at 6.3× forward earnings against a peer median of 38.8× (cheapest of 5).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -36%, so the hurdle is +21 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$842M | HK$58.0M | HK$169M | HK$70.2M | HK$111M |
| Revenue growth | — | -66% | +141% | -37% | — |
| Gross profit | HK$795M | HK$32.7M | HK$140M | -HK$23.4M | HK$62,795 |
| EBITDA | HK$598M | -HK$160M | -HK$207M | -HK$432M | -HK$537M |
| Net income | HK$589M | -HK$158M | -HK$169M | -HK$397M | -HK$432M |
| Free cash flow | HK$622M | -HK$208M | -HK$55.3M | -HK$423M | -HK$362M |
| Capital expenditure | HK$1.76M | HK$1.81M | HK$13.1M | HK$42.7M | HK$19.2M |
| Total debt | n/a | HK$359M | HK$275M | HK$296M | HK$166M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1167.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -23.7% | -13.9% | 4th lowest of 21 |
| 6-month return | -27.4% | -5.3% | 5th lowest of 20 |
| Distance from 52-week high | -49.8% | -37.3% | 6th lowest of 21 |
| Revenue growth (TTM) | +286.2% | -4.0% | highest of 15 |
| Operating margin | 68.0% | -27.2% | highest of 16 |
| Forward P/E | 6.3× | 38.8× | cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | -14.9% | 15.2% | least demanding of 6 |
| Growth delivered (Del g) | -36.1% | +0.5% | 2nd lowest of 6 |
| Hurdle (Req g minus delivered) | +21.3 pp | +14.7 pp | 3rd most demanding of 6 |
| EV / EBITDA | 3.5× | n/a | — |
| Net debt / EBITDA | -2.6× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 6.3× | -14.9% | -36.1% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | n/a | 6.0% | -62.3% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 187.6× | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | n/a | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | n/a | 31.8% | -3.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 43.8× | 15.2% | +0.5% |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 33.9× | 18.2% | +7.3% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | n/a | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 28.6× | 5.8% | +70.5% |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | n/a | n/a | n/a |